sovihep D Description The active substance is Sofosbuvir and Daclatasvir ( sovihep d tablet ), which is an inhibitor of the NS5A protein required for the synthesis of HCV. The main purpose of the sovihep d is antiviral therapy. It is active in the fight against viral hepatitis C (genotypes 1, 2, 3, 4). The essence of the impact is to block the development of HCV and its spread in the body of the carrier. HCV exists in different forms known as genotypes. Genotype 1 is the most common type of HCV genotype and sovihep d tablet is also the most difficult to treat using other treatments. Mechanism of Action: DCV is an HCV NS5A replication complex inhibitor. This NS5A sovihep d viral protein has enzymatic activity that is essential for HCV RNA replication and assembly. In replication it appears to play a role in the formation of a membranous web along with viral protein NS4B, and this web provides a platform for replication. The NS5A protein is composed of 3 domains; Domains I a
Drug profile of Xbira xbira 250mg tablet are containing an active component known as Abiraterone acetate which exhibits anti-tumor activity against prostate cancer. xbira 250mg Cipla is a derivative of androstene, which involves in the prohibition process of steroid 17 alpha hydroxylase and containing anti-neoplastic activity. Abiraterone acetate xbira is an oral tablet which is an active acetate ester form of steroidal compound known as Abiraterone with anti-androgenic activity. Abiraterone acetate xbira 250mg tablet is involved by interfering with testosterone activity by inhibiting the synthesis. PRODUCT DETAILS Brand name: Xbira Active substance: Abiraterone acetate Strength: 250mg Mfg: Cipla Pack: 120 tablets in a container Classified as: Anti-neoplastic agent Prescribing information of Xbira The most important indication of xbira 250mg tablet is; Metastatic castration resistance prostate cancer Metastatic high risk castration sensitive prostate cancer Involved